DNMT3B and neoplasm: Specifically, our group has recently demonstrated the overexpression of DNMT3A and DNMT3B in ERMS primary tumor biopsies (251) and highlighted the synergic impact of DNMT3A or DNMT3B silencing and irradiation on viability and aggressiveness of RMS cells, suggesting that DNMT inhibitors could have a clinical application in combination with standard RT in the clinical management of patients with RMS.